SRNE News and Press, Sorrento Therapeutics Inc. From 09/30/20

At the beginning of this year, Sorrento Therapeutics (NASDAQ: SRNE) was focused on its pain management drug, resiniferatoxin, as well as its Dimeric Antigen Receptor-T (DAR-T) cell therapy targeting various blood cancers and solid tumors. But the biotech has made a major piv...

Sorrento Therapeutics (SRNE) inks an agreement with ViralClear Pharmaceuticals, parent of BioSig Technologies (BSGM), aimed at exploring the potential of small molecule and antibody combination therapies in COVID-19.SRNE will initially contribute neutralizing antibody STI-1400 while ViralClea...

Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model of Golden Syrian hamster. ViralClear to contribute its oral antiviral Merime...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) were surging 10.5% higher as of 11:07 a.m. EDT on Tuesday. The nice gain came following the company's announcement late Monday evening of encouraging preclinical data for its experimental COVID-19 antibody therapies STI-1499 and STI-202...

U.S. Energy (USEG) +168% after entering producing assets purchase agreement.Houston American Energy (HUSA) +77%.PEDEVCO (PED) +56%.Greenpro Capital Corp. (GRNQ) +53%.Flux Power Holdings (FLUX) +36% on FY results.Mexco Energy (MXC) +33%.Westwater Resources (WWR) +30%.New Co...

Sorrento Therapeutics (SRNE) shares up 6% in premarket, in reaction to preclinical data on COVI-GUARD (STI-1499) and COVI-AMG (STI-2020) antibodies against SARS-CoV-2, and both demonstrated neutralizing activities against SARS-CoV-2 virus infection.In May, it announced that STI...

In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus. Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2 infection in Syrian gold...

Sorrento ([[SRNE]] +7.3%) reports positive results from a Phase 1b clinical trial evaluating resiniferatoxin ((RTX)) in patients with moderate-to-severe pain due to osteoarthritis of the knee.98.8% (n=83/84) of patients experienced a treatment-emergent adverse event ((TEAE)) but only 6% ...

Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled. No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months post-administration. The study is scheduled to complete the last patient follow-up (1 ye...

Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported, and a majority of patients reported meaningful pain reduction of 30% or more vs. baseline.Sorrento (SRNE) expects to immediately submit to the FDA a request to procee...